383 related articles for article (PubMed ID: 15234234)
1. Clinical utility of cytokeratins as tumor markers.
Barak V; Goike H; Panaretakis KW; Einarsson R
Clin Biochem; 2004 Jul; 37(7):529-40. PubMed ID: 15234234
[TBL] [Abstract][Full Text] [Related]
2. Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease.
van Dalen A
Anticancer Res; 1996; 16(4B):2345-9. PubMed ID: 8694567
[TBL] [Abstract][Full Text] [Related]
3. Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia.
Tramonti G; Ferdeghini M; Donadio C; Norpoth M; Annichiarico C; Bianchi R; Bianchi C
Cancer Detect Prev; 2000; 24(1):86-90. PubMed ID: 10757127
[TBL] [Abstract][Full Text] [Related]
4. Cyfra 21-1 and TPA as markers in malignant mesothelioma.
Bonfrer JM; Schouwink JH; Korse CM; Baas P
Anticancer Res; 1997; 17(4B):2971-3. PubMed ID: 9329578
[TBL] [Abstract][Full Text] [Related]
5. Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis.
Sheard MA; Vojtesek B; Simickova M; Valik D
J Cell Biochem; 2002; 85(4):670-7. PubMed ID: 11968007
[TBL] [Abstract][Full Text] [Related]
6. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma.
Tai CJ; Liu FY; Liang JA; Yang SN; Tsai MH; Kao CH
Anticancer Res; 2002; 22(6B):3793-6. PubMed ID: 12552995
[TBL] [Abstract][Full Text] [Related]
7. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
[TBL] [Abstract][Full Text] [Related]
8. [Cytokeratin detection as a diagnostic tool in oncology].
Galus R; Włodarski K
Pol Merkur Lekarski; 2007 Sep; 23(135):209-11. PubMed ID: 18080697
[TBL] [Abstract][Full Text] [Related]
9. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy.
Wakatsuki M; Suzuki Y; Nakamoto S; Ohno T; Ishikawa H; Kiyohara H; Kiyozuka M; Shirai K; Nakayama Y; Nakano T
J Gastroenterol Hepatol; 2007 May; 22(5):715-9. PubMed ID: 17444861
[TBL] [Abstract][Full Text] [Related]
10. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy.
Andreadis C; Touloupidis S; Galaktidou G; Kortsaris AH; Boutis A; Mouratidou D
J Urol; 2005 Nov; 174(5):1771-5; discussion 1775-6. PubMed ID: 16217281
[TBL] [Abstract][Full Text] [Related]
11. Cytokeratin fragments in the serum: their utility for the management of oral cancer.
Sawant SS; Zingde SM; Vaidya MM
Oral Oncol; 2008 Aug; 44(8):722-32. PubMed ID: 18203649
[TBL] [Abstract][Full Text] [Related]
12. Cyfra 21.1, TPS and SCC in squamous cell carcinoma of larynx.
Monteiro E; Varzim G; Crespo M; Araújo L
An Otorrinolaringol Ibero Am; 2003; 30(5):467-79. PubMed ID: 14648927
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS.
Mady EA
Int J Biol Markers; 2001; 16(2):130-5. PubMed ID: 11471896
[TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness of tumor markers in squamous cell carcinoma of the larynx.
Eleftheriadou A; Chalastras T; Ferekidou E; Kyriou L; Yiotakis I; Pappas Z; Ferekidis E; Kandiloros D
Anticancer Res; 2006; 26(3B):2493-7. PubMed ID: 16821638
[TBL] [Abstract][Full Text] [Related]
15. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of serum cytokeratin-19 fragment (CYFRA 21-1) in hepatocellular carcinoma.
Uenishi T; Yamazaki O; Yamamoto T; Hirohashi K; Tanaka H; Tanaka S; Hai S; Ono K; Kubo S
J Hepatobiliary Pancreat Surg; 2006; 13(3):239-44. PubMed ID: 16708302
[TBL] [Abstract][Full Text] [Related]
17. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma.
Uenishi T; Yamazaki O; Tanaka H; Takemura S; Yamamoto T; Tanaka S; Nishiguchi S; Kubo S
Ann Surg Oncol; 2008 Feb; 15(2):583-9. PubMed ID: 17955299
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of tissue polypeptide antigen determination in lung cancer management.
Rapellino M; Pecchio F; Baldi S; Scappaticci E; Cavallo A
Anticancer Res; 1995; 15(3):1065-70. PubMed ID: 7645927
[TBL] [Abstract][Full Text] [Related]
19. [New tumour markers useful in diagnostics and monitoring of cervical cancer].
Bedkowska GE; Lawicki S; Szmitkowski M
Przegl Lek; 2007; 64(12):1022-7. PubMed ID: 18595508
[TBL] [Abstract][Full Text] [Related]
20. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]